Johnson & Johnson has agreed to acquire Proteologix for $850 million in cash. The purchase will add bispecific antibody assets to treat atopic dermatitis to its dermatology portfolio, in particular, the bispecific antibody PX128 that targets interleukin 13 plus thymic stromal lymphopoietin.